A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions [EXTENSION OF 700020910]

Trial Profile

A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions [EXTENSION OF 700020910]

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 May 2014

At a glance

  • Drugs Everolimus (Primary) ; Sirolimus
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms XIENCE V: SPIRIT WOMEN Sub-study
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 06 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top